Ulcerative Colitis

Centocor Inc., a wholly owned subsidiary of Johnson & Johnson, discovered REMICADE and has exclusive marketing rights to the product in the US.

Meanwhile, Schering-Plough markets REMICADE in all countries outside the US, except in Japan and China.

REMICADE, a monoclonal antibody that specifically targets TNF-alpha, plays a role in Crohn's disease/CD, rheumatoid arthritis/RA, ankylosing spondylitis/AS, psoriatic arthritis/PsA, psoriasis and The company noted that REMICADE is the only anti-TNF biologic therapy available as an IV form.

With the approval, REMICADE became the first biologic therapy to treat moderately to severely active UC in the EU, the company noted.

The approval also marks the eighth indication REMICADE has received in the EU for the treatment of immune-mediated inflammatory disorders.

The approval of REMICADE for UC was based on data from the Active The multi-center, Phase 3, randomized, double-blind, placebo-controlled, clinical trials were conducted to evaluate the safety and efficacy of REMICADE for the treatment of adult patients with moderately to severely active UC, with an inadequate response to conventional therapy.

The company noted that REMICADE is now approved in...

Read more...